CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension

  • CEL-SCI Corporation CVM reported new data from its pivotal Phase 3 study of Multikine (Leukocyte Interleukin) in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • The new data presented focuses exclusively on the patient population (n=352) from the IT-MATTERS study for which CEL-SCI is seeking regulatory marketing approval for locally advanced primary head and neck cancer patients scheduled to receive radiotherapy, but not chemotherapy, after surgery.
  • Related: 10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients.
  • Key study findings include:
    • The overall survival advantage accelerated and increased, with Multikine+CIZ to the treatment regimen as compared to Standard of Care (SOC) alone increasing from 2.8% at three years to 8.3% at four years to 15.6% at 5 years, with a 49.7% survival for control vs. 65.3% for the Multikine treated group at 5 years.
    • The hazard ratio was 0.70 representing a 43% survival extension.
    • Progression-free survival was 8.4% higher at five years for patients treated with Multikine+ CIZ+SOC than those treated with SOC control alone.
    • 16.5% of these patients were early tumor responders with Multikine compared to 0% of patients treated with SOC alone.
    • Multikine patients who had an early tumor response had significantly improved survival. Their death rate was only 15.6% vs. 48.7% death rate for the control patients.
    • Even the patients who did not have an early tumor response had better survival than the control group patients, with a 43.8% death rate vs. a 48.7% death rate for control.
  • Price Action: CVM shares are up 1.73% at $2.94 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!